{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T14:00:45Z","timestamp":1792677645050,"version":"4.5.0"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T00:00:00Z","timestamp":1701820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["29685"],"award-info":[{"award-number":["29685"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015570","name":"Blood Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018955","name":"Leeds Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018955","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Epidemiology"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.canep.2023.102513","type":"journal-article","created":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T05:55:50Z","timestamp":1703915750000},"page":"102513","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK\u2019s Haematological Malignancy Research Network"],"prefix":"10.1016","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1284-9912","authenticated-orcid":false,"given":"Maxine","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Painter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Howell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Barrans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Cargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"de Tute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reuben","family":"Tooze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathy","family":"Burton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0925-9014","authenticated-orcid":false,"given":"Russell","family":"Patmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7603-3704","authenticated-orcid":false,"given":"Eve","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1111-966X","authenticated-orcid":false,"given":"Alexandra","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.canep.2023.102513_bib1","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J. Clin."},{"issue":"11","key":"10.1016\/j.canep.2023.102513_bib2","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jamaoncol.2018.2706","article-title":"Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study","volume":"4","author":"Global Burden of Disease Cancer Collaboration","year":"2018","journal-title":"JAMA Oncol."},{"issue":"7","key":"10.1016\/j.canep.2023.102513_bib3","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.canep.2023.102513_bib4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.canep.2023.102513_bib5","series-title":"World Health Organization classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues","year":"2001"},{"key":"10.1016\/j.canep.2023.102513_bib6","series-title":"WHO Classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.canep.2023.102513_bib7","series-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.canep.2023.102513_bib8","series-title":"International classification of diseases for oncology: ICD-O","author":"Fritz","year":"2000"},{"issue":"11","key":"10.1016\/j.canep.2023.102513_bib9","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1038\/bjc.2011.450","article-title":"Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network","volume":"105","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.canep.2023.102513_bib10","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.respe.2015.12.017","article-title":"Cancer incidence in France over the 1980\u20132012 period: Hematological malignancies","volume":"64","author":"Le Guyader-Peyrou","year":"2016","journal-title":"Rev. d\u2032\u00c9pid\u00e9miologie Et. De. St. Publique"},{"issue":"2","key":"10.1016\/j.canep.2023.102513_bib11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.2012.064014","article-title":"Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study","volume":"98","author":"Maynadi\u00e9","year":"2013","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.canep.2023.102513_bib12","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.3109\/10428194.2014.956315","article-title":"The heterogeneity of changes in incidence and survival among lymphoid malignancies in a 30-year French population-based registry","volume":"56","author":"Dandoit","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.canep.2023.102513_bib13","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.3324\/haematol.2013.084061","article-title":"Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain","volume":"98","author":"Osca-Gelis","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.canep.2023.102513_bib14","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canep.2018.11.001","article-title":"Population-based incidence of lymphoid neoplasms: Twenty years of epidemiological data in the Girona province, Spain","volume":"58","author":"Villavicencio","year":"2019","journal-title":"Cancer Epidemiol."},{"issue":"19","key":"10.1016\/j.canep.2023.102513_bib15","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"issue":"n\/a","key":"10.1016\/j.canep.2023.102513_bib16","first-page":"23","article-title":"Sex differences in lymphoma incidence and mortality by subtype: a population-based study","volume":"98","author":"Radkiewicz","year":"2022","journal-title":"Am. J. Haematol."},{"issue":"9","key":"10.1016\/j.canep.2023.102513_bib17","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1038\/bjc.2015.94","article-title":"Lymphoma incidence, survival and prevalence 2004-2014: sub-type analyses from the UK\u2019s Haematological Malignancy Research Network","volume":"112","author":"Smith","year":"2015","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canep.2023.102513_bib18","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: occurrence, progression and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004-15","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol."},{"issue":"6","key":"10.1016\/j.canep.2023.102513_bib19","doi-asserted-by":"crossref","first-page":"443","DOI":"10.3322\/caac.21357","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canep.2023.102513_bib20","unstructured":"Surveillance, Epidemiology and End Results Program [Internet]. 2023 [cited 2023 Aug 31]. SEER Cancer Stat Facts. Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/index.html\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib21","unstructured":"National Cancer Registration and Analysis Service (NCRAS). Get Data Out programme. [cited 2023 Jun 21]. CancerData. Available from: \u3008https:\/\/www.cancerdata.nhs.uk\/getdataout\u3009."},{"issue":"4","key":"10.1016\/j.canep.2023.102513_bib22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/s41591-022-01738-x","article-title":"Priorities for cancer research in low- and middle-income countries: a global perspective","volume":"28","author":"Pramesh","year":"2022","journal-title":"Nat. Med"},{"key":"10.1016\/j.canep.2023.102513_bib23","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyy044","article-title":"Cohort Profile: the Haematological Malignancy Research Network (HMRN); a UK population-based patient cohort","author":"Smith","year":"2018","journal-title":"Int J. Epidemiol. [Internet]"},{"key":"10.1016\/j.canep.2023.102513_bib24","unstructured":"Overview | Haematological cancers: improving outcomes | Guidance | NICE [Internet]. NICE; 2016 [cited 2023 Nov 29]. Available from: \u3008https:\/\/www.nice.org.uk\/guidance\/ng47\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib25","unstructured":"Population estimates for the UK, England and Wales, Scotland and Northern Ireland - Office for National Statistics [Internet]. [cited 2023 Apr 17]. Available from: \u3008https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/bulletins\/annualmidyearpopulationestimates\/mid2016\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib26","unstructured":"Eurostat. Revision of the European Standard Population - Report of Eurostat\u2019s task force - 2013 edition [Internet]. 2013 [cited 2018 Jan 26]. Available from: \u3008http:\/\/ec.europa.eu\/eurostat\/web\/products-manuals-and-guidelines\/-\/KS-RA-13\u2013028\u3009."},{"issue":"1","key":"10.1016\/j.canep.2023.102513_bib27","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1177\/1536867X1501500112","article-title":"Estimating and modeling relative survival","volume":"15","author":"Dickman","year":"2015","journal-title":"Stata J."},{"issue":"1","key":"10.1016\/j.canep.2023.102513_bib28","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1541-0420.2011.01640.x","article-title":"On estimation in relative survival","volume":"68","author":"Perme","year":"2012","journal-title":"Biometrics"},{"key":"10.1016\/j.canep.2023.102513_bib29","unstructured":"Office of National Statistics. Single-year life tables, UK: 1980 to 2020 - Office for National Statistics [Internet]. 2022 [cited 2022 Oct 6]. Available from: \u3008https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/lifeexpectancies\/datasets\/singleyearlifetablesuk1980to2018\u3009."},{"issue":"15","key":"10.1016\/j.canep.2023.102513_bib30","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1016\/j.ejca.2004.07.002","article-title":"Standard cancer patient population for age standardising survival ratios","volume":"40","author":"Corazziari","year":"2004","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.canep.2023.102513_bib31","doi-asserted-by":"crossref","first-page":"545","DOI":"10.3109\/02841861003739322","article-title":"Trends in the survival of patients diagnosed with cancer in the Nordic countries 1964\u20132003 followed up to the end of 2006. Material and methods","volume":"49","author":"Engholm","year":"2010","journal-title":"Acta Oncol."},{"key":"10.1016\/j.canep.2023.102513_bib32","unstructured":"nordcansurvival\u00b7CancerRegistryOfNorway\/NORDCAN Wiki\u00b7GitHub [Internet]. [cited 2023 Aug 22]. Available from: \u3008https:\/\/github.com\/CancerRegistryOfNorway\/NORDCAN\/wiki\/nordcansurvival\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib33","unstructured":"Stata Statistical Software: Release 18. College Station, TX: StataCorp LLC.: StataCorp; 2023."},{"key":"10.1016\/j.canep.2023.102513_bib34","doi-asserted-by":"crossref","first-page":"1182971","DOI":"10.3389\/fonc.2023.1182971","article-title":"Incidence, mortality, and survival of hematological malignancies in Northern Italian patients: an update to 2020","volume":"13","author":"Mangone","year":"2023","journal-title":"Front Oncol."},{"key":"10.1016\/j.canep.2023.102513_bib35","unstructured":"Surveillance, Epidemiology and End Results Program [Internet]. 2023 [cited 2023 Aug 28]. Myeloma - Cancer Stat Facts. Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib36","unstructured":"Myeloma incidence statistics | Cancer Research UK [Internet]. [cited 2023 Aug 28]. Available from: \u3008https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/incidence#heading-Zero\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib37","series-title":"Hematopoietic and Lymphoid Neoplasm Coding Manual [Internet]","author":"Ruhl","year":"2020"},{"issue":"9","key":"10.1016\/j.canep.2023.102513_bib38","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.ejca.2014.02.008","article-title":"Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnoses","volume":"51","author":"Gavin","year":"2015","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canep.2023.102513_bib39","article-title":"Epidemiological Characteristics of Peripheral T-Cell Lymphoma: A Population-Based Study","author":"Liu","year":"2022","journal-title":"Front. Oncol. [Internet]"},{"issue":"5","key":"10.1016\/j.canep.2023.102513_bib40","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-C\u00e9ligny","year":"2004","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.canep.2023.102513_bib41","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.canep.2023.102513_bib42","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2008","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.canep.2023.102513_bib43","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/0284186X.2015.1026455","article-title":"Male gender is an adverse risk factor only in young patients with diffuse large B-cell lymphoma - a Swedish population-based study","volume":"54","author":"Hedstr\u00f6m","year":"2015","journal-title":"Acta Oncol."},{"key":"10.1016\/j.canep.2023.102513_bib44","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1200\/EDBK_175447","article-title":"Age and sex in non-Hodgkin lymphoma therapy: it\u2019s not all created equal, or is it?","volume":"37","author":"Pfreundschuh","year":"2017","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"3","key":"10.1016\/j.canep.2023.102513_bib45","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1007\/s11864-020-0715-5","article-title":"Novel therapies in chronic lymphocytic leukemia: a rapidly changing landscape","volume":"21","author":"Iovino","year":"2020","journal-title":"Curr. Treat. Options Oncol."},{"issue":"1","key":"10.1016\/j.canep.2023.102513_bib46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3324\/haematol.2021.278717","article-title":"Prospects in the management of patients with follicular lymphoma beyond first-line therapy","volume":"107","author":"Qualls","year":"2022","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.canep.2023.102513_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11864-021-00840-5","article-title":"Novel therapies in the treatment of Hodgkin lymphoma","volume":"22","author":"Andrade-Gonzalez","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"issue":"15","key":"10.1016\/j.canep.2023.102513_bib48","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1016\/j.ejca.2015.08.003","article-title":"Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000\u20132007: Results of EUROCARE-5 population-based study","volume":"51","author":"De Angelis","year":"2015","journal-title":"Eur. J. Cancer"},{"issue":"5","key":"10.1016\/j.canep.2023.102513_bib49","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.canep.2023.102513_bib50","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.canep.2023.102513_bib51","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.3324\/haematol.2017.183475","article-title":"Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study","volume":"103","author":"Thorsteinsdottir","year":"2018","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.canep.2023.102513_bib52","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.15170","article-title":"Impact of novel therapies for mantle cell lymphoma in the real world setting: a report from the UK\u2019s Haematological Malignancy Research Network (HMRN)","volume":"181","author":"Smith","year":"2018","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.canep.2023.102513_bib53","unstructured":"Cancer Research UK [Internet]. 2015 [cited 2023 Oct 15]. Chronic lymphocytic leukaemia (CLL) incidence statistics. Available from: \u3008https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/leukaemia-cll\/incidence\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib54","unstructured":"Cancer Research UK [Internet]. 2015 [cited 2023 Oct 15]. Myeloma incidence statistics. Available from: \u3008https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma\/incidence\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib55","unstructured":"Cancer Research UK [Internet]. 2015 [cited 2023 Oct 15]. Non-Hodgkin lymphoma incidence statistics. Available from: \u3008https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/non-hodgkin-lymphoma\/incidence\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib56","unstructured":"SEER [Internet]. [cited 2023 Oct 15]. Follicular Lymphoma - Cancer Stat Facts. Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/follicular.html\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib57","unstructured":"SEER [Internet]. [cited 2023 Oct 15]. Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma - Cancer Stat Facts. Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/cllsll.html\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib58","unstructured":"SEER [Internet]. [cited 2023 Oct 15]. Diffuse Large B-Cell Lymphoma - Cancer Stat Facts. Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/dlbcl.html\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib59","unstructured":"SEER [Internet]. [cited 2023 Oct 15]. Acute Lymphocytic Leukemia - Cancer Stat Facts. Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/alyl.html\u3009."},{"key":"10.1016\/j.canep.2023.102513_bib60","unstructured":"SEER [Internet]. [cited 2023 Oct 15]. Myeloma - Cancer Stat Facts. Available from: \u3008https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html\u3009."},{"issue":"11","key":"10.1016\/j.canep.2023.102513_bib61","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.canep.2023.102513_bib62","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation In Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med"}],"container-title":["Cancer Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782123001935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1877782123001935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T10:27:59Z","timestamp":1736418479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1877782123001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":62,"alternative-id":["S1877782123001935"],"URL":"https:\/\/doi.org\/10.1016\/j.canep.2023.102513","relation":{},"ISSN":["1877-7821"],"issn-type":[{"value":"1877-7821","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lymphoid blood cancers, incidence and survival 2005-2023: A report from the UK\u2019s Haematological Malignancy Research Network","name":"articletitle","label":"Article Title"},{"value":"Cancer Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canep.2023.102513","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102513"}}